Real-life effectiveness of Indacaterol/Glycopyrronium/Mometasone for symptomatic relief of cough after switching from ICS/LABA therapy in patients with asthma

Start Date12 Oct 2022

Sponsor / Collaborator

Novartis Pharma KK

CTRI/2021/12/038978

/ Not yet recruitingNot Applicable

An International, Open, Randomized, Comparative study of the efficacy and safety of the medicinal products Glycopyrronium bromide plus Indacaterol 50 plus 110 Î¼g inhalation powder capsules (PSK Pharma LLC, Russia) and Ultibro Breezhaler 50 plus 110Î¼g inhalation powder capsules(Novartis Pharma AG, Switzerland) in subjects with COPD

Start Date31 Dec 2021

Sponsor / Collaborator-

CTRI/2021/10/037155

/ CompletedPhase 3

A prospective, randomized, double blind, parallel, multicentre, phase III clinical trial to assess the efficacy and safety of Indacaterol and Budesonide Inhalation as compared to Formoterol Fumarate and Budesonide Inhalation in patients with Chronic Obstructive Pulmonary Disease.

Start Date18 Oct 2021

Sponsor / Collaborator

Zydus Healthcare Ltd.

100 Clinical Results associated with Indacaterol acetate

100 Translational Medicine associated with Indacaterol acetate

100 Patents (Medical) associated with Indacaterol acetate

701

Literatures (Medical) associated with Indacaterol acetate

01 Jun 2025·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying

Article

Author: Coeurderoi, Alice ; Evrard, Brigitte ; Sacré, Pierre-Yves ; Piel, Géraldine ; Cataldo, Didier ; Bya, Laure-Anne ; Bottero, Benedetta ; Dinh, Tuan Nghia ; Ziemons, Eric ; Lechanteur, Anna

Dry powders for inhalation are evolving to address the challenge of maximizing lung deposition, with growing interest in carrier-free formulations shaping future therapies. This study focuses on developing an inhalation powder with optimal properties, combining ciclesonide and indacaterol, a combination treatment for asthma not yet available on the market. Using spray-drying technology with cyclodextrins, ultra-flying microparticles aim to be produced to enhance aerosolization and therapeutic efficacy. Cyclodextrin screening identified Crysmeb as the most effective for ciclesonide complexation, enabling stable solution atomization, while HPβCD was selected to create deflated particle shapes in a spray-dried suspension. The impact of active pharmaceutical ingredient solubilization state and solid content on powder properties was investigated, revealing that the solutions provided a more suitable particle size distribution for inhalation. Moreover, the atomized solutions led to fine particle fractions exceeding 60 % for both drugs, outperforming commercial products due to this enhanced distribution. Aerodynamic performance was further assessed under reduced flow rates using the Next Generation Impactor, showing no significant reduction in lung deposition at 60 L/min for atomized solutions. The optimized powders also demonstrated higher lung deposition of indacaterol maleate compared to Onbrez®, with findings confirmed using the PreciseInhale® system, providing comprehensive insights into aerosolization behavior. These results highlight the importance of advancing in vitro methods to better predict in vivo performance and support the development of more effective inhaled therapies. Overall, this work presents a stable, carrier-free inhalation powder with a novel drug combination that achieves efficient lung deposition and six-month stability.

01 Jun 2025·JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Genomic crosstalk between carbachol, a muscarinic receptor agonist, and the long-acting β2-adrenoceptor agonist, indacaterol, in human airway epithelial cells

Article

Author: Charlton, Steven J ; Paracha, Tamkeen U ; Wang, Yanqun ; Maillet, Ashley ; Newton, Robert ; Joshi, Radhika ; Mostafa, Mahmoud M ; Bauer, Carla M T ; Ruda, Vera M ; Iartchouk, Oleg ; Morris, Melody K ; Joshi, Taruna ; Kooi, Cora ; Sandham, David A ; Jayasinghe, Varuna ; Giembycz, Mark A

Many patients with chronic obstructive pulmonary disease are susceptible to recurrent exacerbations. In this study, we hypothesized that endogenous acetylcholine (ACh) may act as a proinflammatory mediator because long-acting muscarinic receptor antagonists protect against exacerbations, which have an inflammatory basis. This possibility was explored by determining if carbachol (CCh), a stable ACh analog, was a genomic stimulus in BEAS-2B bronchial epithelial cells. The ability of CCh to interact with indacaterol (Ind), a long-acting β₂-adrenoceptor agonist, was also assessed given that (1) sympathomimetic bronchodilators can promote adverse gene expression changes in airway structural cells, and (2) crosstalk between β₂-adrenoceptor and Gq-coupled muscarinic receptor agonists is well described. Unlike Ind, which induced 624 unique genes, CCh was a relatively weak genomic stimulus, implying that ACh may not behave as a proinflammatory mediator as hypothesized. Nevertheless, checkerboard assays using BEAS-2B cells expressing a cAMP-response element luciferase reporter determined that CCh interacted with Ind in a supra-additive manner and that this interaction was replicated on 39 Ind-regulated genes. Functional annotation of the Ind-regulated transcriptomes identified "transcription" and "signalling" as the dominant themes, with gene ontology terms associated with "inflammation" and "immune processes" being highly represented. A comparable gene ontology signature was obtained when Ind and CCh were combined; however, the number, magnitude and duration of gene expression changes were significantly enhanced. If genomic interactions occur between a long-acting β₂-adrenoceptor agonist and ACh in vivo, then they may enhance the expression of adverse-effect genes that could maintain, or even augment, features of lung pathology in chronic obstructive pulmonary disease. SIGNIFICANCE STATEMENT: Long-acting muscarinic receptor antagonists reduce exacerbation risk in chronic obstructive pulmonary disease, implying the etiology could have an inflammatory basis mediated by acetylcholine. However, in BEAS-2B cells, carbachol was a weak genomic stimulus, although it enhanced changes in indacaterol-regulated gene expression. Functional annotation of carbachol + indacaterol-regulated genes identified gene ontology terms associated with several themes, including inflammation. Interaction between a long-acting β₂-adrenoceptor agonist and endogenous acetylcholine could, paradoxically, augment airway inflammation in patients with chronic obstructive pulmonary disease.

01 May 2025·ANALYTICAL BIOCHEMISTRY

Different manipulations for resolving the overlapped spectra of novel anti-asthmatic combination: Green-blue-white triple evaluation tools

Article

Author: Khalil, Hawa ; Bahgat, Eman A ; Reda, Alaa ; Fawzy, Michael Gamal

This work represents different spectrophotometric techniques for concurrent quantification of Indacaterol (IND) and Mometasone furoate (MOM); co-formulated inhalation capsules to control asthma symptoms. Direct spectrophotometric (D⁰) approach was applied for IND assay. While, absorption factor (AF), ratio difference (RD), mean centering of the ratio spectra (MC), and continuous wavelet transform (CW) techniques were utilized for MOM quantification. The applied methods' validation was accomplished relative to the ICH guidelines. Within the linearity range of (4-20 μg/mL), these approaches provided accurate and precise assessment of IND and MOM in laboratory-synthetic mixtures and pharmaceutical formulation with determination coefficients higher than 0.9997. Moreover, the proposed methods demonstrated good detection and quantification levels. The respective LOD and LOQ for IND were (0.33 μg/mL) and (1.01 μg/mL). While, the LOD and LOQ for MOM were ranging from (0.16-0.30 μg/mL) and (0.47-0.91 μg/mL), respectively. Statistical comparison revealed no significant differences between the findings derived from the proposed methods and the reported one. The applied methods' environmental effect was cheeked using Analytical Greenness Calculator (AGREE), Blue Applicability Grade Index (BAGI), and Red-Green-Blue 12 (RGB12). All the utilized metrics showed reliable scores, approving that the proposed methods were adhered to the sustainability principles.

News (Medical) associated with Indacaterol acetate

21 Mar 2024

·synapse.patsnap.com

GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (5)

In this article, we will focus on Sosei Heptares, a leading company in the field of GPCR new drug development, and its GPCR research and development pipeline. For more details, please follow the link below. GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (1)GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (2)GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (3)GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (4)Sosei Heptares in JPM 2024Sosei Heptares is a biopharmaceutical company based in Japan with operations spanning the Asia-Pacific region, focused on structure-based drug design (SBDD), particularly in the area of G protein-coupled receptors (GPCRs). The company has over 30 active research and development projects involving central nervous system disorders, immunology, gastrointestinal diseases, and various other therapeutic areas. Its marketed product, PIVLAZ®, is widely used in Japan and South Korea, where it has been approved for use. Over the past 20 years, Sosei has undergone several rounds of acquisitions and restructurings and completed a significant transformation in 2023, including the acquisition of Idorsia Pharmaceuticals' operations in Japan and the Asia-Pacific region and securing significant investments from government funds. Additionally, the company has collaborated with several top global pharmaceutical companies, making clinical advancements in the treatment of metabolic and neuropsychiatric disorders such as insomnia. Daridorexant is expected to be launched in Japan by the end of 2024. In 2023, Sosei Heptares has implemented a series of corporate actions and investments to drive future growth. The company's internal research projects, including PIVLAZ®, daridorexant, HTL-149 (a GPR52 agonist), and HTL-723, have achieved milestone progress. Moreover, Sosei Heptares and its partners launched multiple clinical programs in 2023, involving the research and development of several innovative therapies for metabolic and neuropsychiatric disorders. This includes a range of novel cholinergic M4 and M1/M4 agonists being developed in collaboration with Neurocrine for the study of schizophrenia and other neuropsychiatric diseases, with some drugs nearing or having entered the late clinical phase. The company's first commercially available medicine, PIVLAZ® (a selective ETA receptor antagonist), has made a significant impact on stroke treatment in Japan and has been accumulating evidence in the real world. PIVLAZ® is recommended by the Japan Stroke Society and has proven to have a definitive therapeutic effect on subarachnoid hemorrhage (SAH), preventing delayed cerebral ischemia and adverse outcomes with a high level of evidence, thus strengthening the confidence of neurosurgeons in prescribing the medication. Additionally, the drug has received market approval in Korea and is planned to start sales to patients at the beginning of 2025. By the end of 2023, the company has submitted a New Drug Application (NDA) in Japan for daridorexant for the treatment of insomnia, with an anticipated launch in the Japanese market in the fourth quarter of 2024. The drug is expected to make a significant contribution to Japanese society. Insomnia causes an estimated annual economic loss of up to 15 trillion yen in Japan (approximately 3% of GDP), and results in the loss of 604,000 working days due to absenteeism and medical leave. Moreover, individuals averaging less than 6 hours of sleep per night face an increased mortality risk by 10%. Daridorexant, a dual orexin receptor antagonist, is already on the market in the United States and Europe under the brand name QUVIVIQ™. Joint development and co-marketing plans for daridorexant in Japan are currently underway, with expectations to effectively address the issue of insomnia. Sosei Heptares employs Artificial Intelligence (AI) and Machine Learning (ML) technologies in various drug development processes to enhance the efficiency of drug discovery, including receptor preparation technology (StaR®), protein structure, molecular design, and translational medicine. Utilizing the StaR® technology in combination with AI/ML algorithms, the company mines datasets rich in GPCR mutations to predict and accelerate the generation of StaR® variants conducive to stabilizing GPCR structures, thereby hastening the drug discovery process. Additionally, AI technology is used to analyze GPCR binding sites and patterns, enhancing the accuracy of GPCR homology models to support drug molecule optimization and virtual screening efforts. Hit identification is conducted based on internal and external structural databases, while drug molecule designs are optimized using ML QSAR models derived from internal and public datasets. Moreover, AI is applied to analyze large patient datasets to identify biomarkers and stratify patients, ensuring more precise and effective clinical trial designs. The application of these advanced technologies not only aids in the identification of new chemical series but also enhances the optimization of existing chemical series, improving drug properties with the goal of developing more life-changing medicines. The company possesses several internally researched and collaboratively developed GPCR (G protein-coupled receptor) new drug development pipelines, which are at various stages of research and development. These pipelines encompass multiple therapeutic areas including metabolic diseases, inflammatory bowel disease, schizophrenia and neuropsychiatric disorders, as well as solid tumors. PIVLAZ® (Clazosentan) is a potent, selective endothelin ETA receptor antagonist indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and ischemic symptoms following aneurysmal subarachnoid hemorrhage (aSAH). Pivlaz® successfully launched in Japan in April 2022 for the treatment of cerebral vasospasm. Sosei Heptares holds the rights to sell Pivlaz® in Japan and the Asia-Pacific region, excluding China. Ultibro Breezhaler is a pioneering inhaled dual bronchodilator (long-acting β2-adrenergic receptor agonist or long-acting muscarinic antagonist, LAMA/LABA), approved in more than 90 countries including the European Union and Japan. It is a once-daily fixed-dose combination formulation of indacaterol and glycopyrronium bromide, indicated in the European Union for the maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Daridorexant is a dual orexin receptor antagonist that blocks the binding and activity of the wakefulness-promoting neuropeptide orexin. In October 2022, daridorexant achieved positive Phase 3 clinical trial results among patients with insomnia in Japan. The success of the trial paved the way for regulatory submission in Japan in the second half of 2023. Daridorexant is approved in the United States and Europe and is marketed by Idorsia under the brand name QUVIVIQ™ in these regions. Sosei Heptares has the rights to sell daridorexant in Japan and the Asia-Pacific region (excluding China). Cenerimod is an S1PR1 modulator currently under Phase 3 clinical investigation for the treatment of systemic lupus erythematosus (SLE). Cenerimod aims to reduce autoimmune responses and control disease activity in patients with SLE by affecting lymphocyte migration. In its collaboration with Idorsia, Sosei Heptares has obtained not only the two key products, PIVLAZ® and daridorexant, but also exclusive options to license cenerimod and lucerastat, as well as selection rights for five additional projects in Idorsia's global pipeline. HTL0016878 is a selective oral small-molecule muscarinic M4 receptor agonist currently in Phase II clinical development for the treatment of schizophrenia. The mechanism of action of HTL0016878 differs from existing antipsychotic medications, and its high selectivity compared to previous non-selective muscarinic receptor agonists offers the potential for improved safety. The GPR52 agonist program is currently in Phase I clinical research, targeting schizophrenia as an indication. GPR52 is an orphan GPCR expressed in the central nervous system, implicated in neural development and regulation of the dopaminergic system. As a potential therapeutic approach, GPR52 agonists aim to ameliorate schizophrenia-related psychopathological symptoms by targeting this receptor. HTL0039732 is a novel, highly selective, and potent EP4 receptor antagonist intended for the clinical treatment of advanced solid tumors by mediating the immunosuppressive effects of PGE2 within the tumor microenvironment. In July 2022, Sosei Heptares signed an agreement with Cancer Research UK to bring Sosei Heptares' cancer immunotherapy candidate into its first human trials. Lotiglipron (PF-07081532) is an oral small-molecule GLP-1R agonist co-developed by Sosei Heptares and Pfizer. Initiated by its partner Pfizer, the Phase I clinical trial of this once-daily oral GLP-1 receptor agonist is expected to improve the metabolic status of patients with diabetes and obesity. At the end of 2022, Sosei Heptares and Pfizer announced the advancement of Lotiglipron (PF-07081532) to Phase II clinical trials. However, in June 2023, Pfizer announced the discontinuation of the clinical development of PF-07081532. At the end of November 2023, Pfizer announced the inclusion of another GLP-1R agonist, PF-06954522, developed in collaboration with Sosei Heptares, into Phase I clinical research. PF-07054894 is a selective small molecule antagonist targeting CCR6 for clinical treatment of inflammatory bowel disease (IBD). This project is also part of a collaborative research program developed with Pfizer. PF-07258669 is a selective antagonist targeting the MC4R receptor co-developed by Sosei Heptares and Pfizer, and is being clinically developed for the treatment of cachexia associated with cancer. NBI-1117570 is a dual agonist product selectively targeting the M1/M4 receptors, intended for the treatment of a variety of psychiatric disorders in the neuropsychiatric field, including but not limited to diseases related to cognition, mood, and behavior. This drug is currently in a Phase 1 clinical development study in collaboration with Neurocrine. NBI-1117569 is a selective small molecule agonist targeting the M4 receptor, while NBI-1117567 is a selective small molecule agonist targeting the M1 receptor. Both different cholinergic receptor agonists were developed using Sosei Heptares' structure-based drug design platform and are involved in neuropsychiatric indications at different stages of research. The former is in a Phase 1 clinical trial, and the latter is ready to enter Phase 1 clinical study; both drugs are being co-developed with Neurocrine. HTL0014242 (TMP-301) is a potent, selective negative allosteric modulator of the mGlu5 receptor discovered by Sosei Heptares, used for the treatment of certain neurological disorders. It is currently in a Phase 1 collaborative development by Tempero Bio for the treatment of substance abuse issues. The EP4 agonist project is currently in the preclinical research phase with indications for inflammatory bowel disease (IBD). The drug is an oral, once-daily small molecule formulation designed to modulate the prostaglandin E2 EP4 receptor subtype within the gastrointestinal tract. By activating the EP4 receptor, the medication may help to regulate immune responses and inflammation processes, thereby alleviating the symptoms of IBD patients. GSK4381406 is a GPR35 receptor agonist co-developed by Sosei Heptares and GSK for the clinical treatment of inflammatory bowel disease, currently in phase 1 clinical research. In November last year, Sosei Heptares announced that, due to GSK's strategic realignment, the company would independently continue the research on the GPR35 receptor agonist project returned by GSK. This orally administered, gut-restricted new drug has the potential to improve intestinal barrier function and reduce visceral pain sensitivity, with plans to re-initiate entry into phase 1 clinical trials.

30 May 2019

·www.biospace.com

Novartis’ Double-Combo Therapy for Asthma Successful in Phase III Trial

lucarista/Shutterstock Novartis’s QMF149 met its primary and key secondary endpoints in the Phase III QUARTZ clinical trial for asthma. QMF149 is a once-daily, fixed-dose combination therapy containing indacaterol acetate, a long-acting beta agonist, and mometasone furoate, an anti-inflammatory. lucarista / Shutterstock Novartis ’ QMF149 met its primary and key secondary endpoints in the Phase III QUARTZ clinical trial for asthma. QMF149 is a once-daily, fixed-dose combination therapy containing indacaterol acetate (IND), a long-acting beta agonist, and mometasone furoate (MF), an anti-inflammatory. It is being developed to treat inadequately controlled asthma. It has been accepted for review by the European Medicines Agency (EMA). The second ingredient, mometasone furoate is exclusively licensed to Novartis from Merck & Co. for use in QMF149. The combination drug showed statistically significant improvements in lung faction. The lung function was measured by trough FEV 1 , which is the volume of air that can be forced out in one second after taking a deep breath. The combination drug was compared to mometasone furoate (MF) alone after 12 weeks of treatment in adults and adolescents. “Despite the number of available treatments, many patients’ lives remain impacted by their asthma,” stated Linda Armstrong, Novartis’ Respiratory Development Unit Head. “The QMF149 results of the QUARTZ study complement the recently presented Phase II data of QVM149 at the 2019 American Thoracic Society Congress, showing superiority of QVM149 to the current standard of care. We look forward to seeing the rest of the data from the PLATINUM clinical trial program.” In addition to improved trough FEV 1 , the combination therapy showed lung function benefit by improvements in PEF compared to the MF. IND/MF showed statistically significant improvements in other measures of lung function over MF alone as well, such as by ACQ-7 after 12 weeks. Both IND/MF and MF alone were generally well tolerated. The overall number of adverse events was lower in the IND/MF group compared to the MF group. Most adverse events in both groups were mild to moderate in severity and were comparable between both cohorts. “I am very pleased with the results of the QUARTZ study looking at the efficacy and safety of the fixed-dose combination of indacaterol and mometasone furoate,” stated Oliver Kornmann, Pulmonary Department, Internal Medicine, University Hospital Mainz, Germany. “Fixed-dose combination inhalers may offer advantages to people with asthma by simplifying complex inhaler regimens, especially when they can be dosed once daily which can therefore further reduce the burden of the disease.” The PLATINUM clinical development program is developing both QMF149, which is what is being reported on today, and a triple formulation, QVM149. QVM149 is a combination of indacaterol acetate, glycopyrronium bromide and mometasone furoate (IND/GLY/MF). This combination has also been accepted for review by the EMA. Glycopyrronium bromide is a long-acting muscarinic receptor antagonist. Glycopyrronium bromide has been exclusively licensed to Novartis since April 2005 by Sosei Heptares and Vectura. There are four clinical trials that are part of the PLATINUM clinical development program. QUARTZ, which is being reported here, compares IND/MF to MF. The PALLADIUM trial compares IND/MF to MF and salmeterol/fluticasone. The IRIDIUM trial compares IND/GLY/MF to IND/MF and salmeterol/fluticasone. And the ARGON trial compares IND/GLY/MF to a combination of salmeterol/fluticasone and tiotropium. Salmterol/fluticasone is marketed under the Advair brand name by GlaxoSmithKline. Tiotropium bromide is marketed as Spiriva Respimat by Boehringer Ingelheim.

Clinical ResultPhase 3Phase 2

09 Mar 2011

·www.pharmatimes.com

Novartis COPD drug indacaterol closer to US green light

Advisors to the US regulator have voted to recommend approval of Novartis' chronic obstructive pulmonary disease drug indacaterol but only at the lower of the two doses proposed by the Swiss drugmaker. The Pulmonary-Allergy Drug Advisory Committee of the US Food and Drug Administration has backed QAB149 (indacaterol) 75 mcg as a once-daily long-term maintenance bronchodilator treatment in patients with COPD, including chronic bronchitis and/or emphysema. The panel voted 13 to four in favour of that dose, but 12 to five against recommending approval of 150 mcg of indacaterol, a long-acting beta2-agonist (LABA). The PADAC noted that 75 mcg was seen as effective as the 150 mcg dose and the committee endorsed the safety of both doses. In October 2009, the FDA issued Novartis with a complete response letter for indacaterol and specifically requested additional information on the dosing. The treatment is already approved in Europe under the tradename Onbrez Breezhaler at 150 and 300 mcg once-daily doses and brought in revenues of $33 million in 2010. If approved in the USA, it will be sold as Arcapta Neohaler. Analysts believe that indacaterol as a monotherapy will only have modest sales but will be lucrative as part of a combo. Jacoba van der Gaag at Datamonitor says that an approval would pave the way for Novartis’ new respiratory franchise, which includes two once-daily combinations using indacaterol; QMF149 with the inhaled corticosteroid mometasone and QVA149 with the long-acting muscarinic antagonist glycopyrrolate. She expects QVA149 to launch in 2013, followed by QMF149 two years later, and Novartis’ indacaterol-containing products to reach $2.4 billion in the seven major markets by 2019, with the majority of sales coming from combos. GlaxoSmithKline’s rival once-daily LABA, GSK642444, is currently in Phase III and a filing is expected later this year but Ms van der Gaag lnotes that COPD patients "have high brand loyalty stemming from hesitation to switch between devices [and] this positive vote for Novartis increases the company’s chances of establishing its brands early, and benefiting from a first mover advantage".

100 Deals associated with Indacaterol acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D11009	Indacaterol acetate	R03AC18	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Phase 2	Slovakia	Novartis Pharma AG	01 Aug 2012
Persistent asthma	Phase 2	Japan	Novartis Pharmaceuticals Corp.	01 Aug 2012
Persistent asthma	Phase 2	Bulgaria	Novartis Pharmaceuticals Corp.	01 Aug 2012
Persistent asthma	Phase 2	Canada	Novartis Pharmaceuticals Corp.	01 Aug 2012
Persistent asthma	Phase 2	Germany	Novartis Pharmaceuticals Corp.	01 Aug 2012
Persistent asthma	Phase 2	Netherlands	Novartis Pharmaceuticals Corp.	01 Aug 2012
Persistent asthma	Phase 2	Poland	Novartis Pharmaceuticals Corp.	01 Aug 2012
Persistent asthma	Phase 2	Slovakia	Novartis Pharmaceuticals Corp.	01 Aug 2012
Persistent asthma	Phase 2	South Korea	Novartis Pharmaceuticals Corp.	01 Aug 2012
Dyspnea	Phase 2	Germany	Novartis AG	01 Feb 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02892019 (Pubmed \| Clin Drug Investig)	Phase 2	Childhood asthma	80	Indacaterol 75 µg	mzmocvnxob(ljnhfpnqpf) = improved rdxiiogasg (ehokysuxwl ) View more	Positive	01 Sep 2023
				Indacaterol 150 µg
NCT02892019 (CTgov)	Phase 2	Asthma	79	Indacaterol acetate 150 μg (Indacaterol Acetate 150 μg o.d.)	dnnlaysxbt(bixavymdes) = ihogaxjbfq hutfmgzdvc (wpiupmjpiz, 0.1664) View more	-	27 Jan 2020
				Indacaterol acetate 75 μg (Indacaterol Acetate 75 μg o.d.)	dnnlaysxbt(bixavymdes) = wgoizqkqmi hutfmgzdvc (wpiupmjpiz, 0.2521) View more
B2208 \| B2209 (ERS2019)	Phase 2	Asthma	-	IND/GLY/MF o.d. 150/50/160 μg	nscdlcglki(fibmdasrsw) = frwqdiyjuu dwrfrjyrxq (bmjvmbjqsa, 66 - 142) View more	-	28 Sep 2019
				IND/GLY/MF o.d. 150/50/80 μg	nscdlcglki(fibmdasrsw) = fjbkfsndbv dwrfrjyrxq (bmjvmbjqsa, 48 - 125) View more
NCT01609478 (CTgov)	Phase 2	Asthma \| Persistent asthma	335	Indacaterol+mometasone furoate (Indacaterol Acetate 75 µg)	ovqfwionjm(cnpmfkfqgl) = unzpejczhs nsclrgnuid (rvectxmmuy, 0.0283) View more	-	09 Sep 2014
				indacaterol+mometasone furoate (Indacaterol Acetate 150 µg)	ovqfwionjm(cnpmfkfqgl) = wsmnxlvsgm nsclrgnuid (rvectxmmuy, 0.0281) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Indacaterol acetate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation